Sleep apnea risk check

What Is Sleep Apnea and How Common Is It Really?

Obstructive sleep apnea (OSA) is a chronic sleep-related breathing disorder characterised by repeated partial or complete collapse of the upper airway during sleep, causing breathing to stop or become severely restricted — typically for 10–90 seconds at a time, dozens to hundreds of times per night. Each apnea event causes a drop in blood oxygen saturation, a spike in sympathetic nervous system activation, and a brief micro-arousal that fragments sleep architecture without the person consciously waking. The result is chronically non-restorative sleep, excessive daytime fatigue, and accumulating physiological damage to the cardiovascular, metabolic, and neurological systems — despite the person believing they are getting adequate sleep.

A 2025 study published in Respiratory Medicine by the American College of Chest Physicians estimated that 83.7 million US adults — 32.4% of the total adult population — have OSA as defined by an Apnea-Hypopnea Index (AHI) of 5 or more events per hour. A landmark ResMed-sponsored study published in The Lancet Respiratory Medicine (August 2025) projected that OSA will affect nearly 77 million diagnosed Americans by 2050 — a 35% increase from 2020 levels — driven by aging demographics and rising BMI. Despite this scale, more than 80% of moderate-to-severe cases go undiagnosed, according to data from multiple large cohort studies. The underdiagnosis problem is particularly severe in women, whose OSA presentation differs from the classic male pattern, leading to significantly delayed recognition and treatment.

Sleep Apnea Symptoms: The Complete List Beyond Snoring

Most people associate sleep apnea exclusively with loud snoring — but snoring is just one of more than a dozen recognised OSA symptoms, and not everyone with OSA snores loudly. The full symptom profile spans sleep-related symptoms, daytime symptoms, and neurological and cardiovascular manifestations. Sleep-related symptoms include: loud snoring (the most recognisable marker); choking, gasping, or sudden waking with difficulty breathing; observed breathing pauses during sleep; frequent nocturnal awakening; nocturia (waking to urinate at night — driven by atrial natriuretic peptide release triggered by the increased cardiac pressure of apnea events); restless sleep; and night sweats. Daytime symptoms include: excessive daytime sleepiness (EDS) — the most functionally impairing symptom; morning headaches (caused by overnight hypercapnia — elevated CO2 from restricted breathing); brain fog and difficulty concentrating; memory impairment; irritability and mood changes; reduced libido; and morning dry mouth or sore throat. Cardiovascular and metabolic symptoms include high blood pressure — particularly difficult-to-control hypertension — and the co-conditions discussed below.

The STOP-Bang Questionnaire: The Clinical Tool Behind This Check

The STOP-Bang questionnaire was developed by Dr. Frances Chung and colleagues at the University Health Network in Toronto, Canada, and first published in Anesthesiology (2008). It has since become the most widely used clinical screening tool for obstructive sleep apnea globally, validated in multiple large populations and used as the standard pre-surgical OSA screening tool in most major hospital systems. The acronym stands for Snoring, Tiredness, Observed apnea, blood Pressure, Body mass index, Age, Neck circumference, and Gender — the eight risk factors most strongly and independently associated with OSA in the original validation study. STOP-Bang scores of 0–2 indicate low OSA risk; 3–4 indicate intermediate risk; 5–8 indicate high risk. Intermediate-risk individuals with additional factors — male sex, BMI above 35, or neck circumference above threshold — are reclassified as high risk.

Our extended 12-question check builds on the STOP-Bang framework by adding clinically relevant factors including morning headaches, nocturia, nocturnal gasping severity, alcohol use, and comorbidity burden — providing a more comprehensive risk picture than the original 8-item tool while remaining accessible for non-clinical self-screening.

Sleep Apnea and Heart Disease: The 71% Risk Elevation

The cardiovascular consequences of untreated obstructive sleep apnea are among the most serious and well-documented in sleep medicine. Research presented at the European Congress on Obesity in April 2026, a collaboration between Imperial College Health Partners, Imperial College Healthcare NHS Trust, and Eli Lilly, found that people with OSA have a 71% higher risk of cardiovascular events or all-cause mortality compared to matched controls — a finding consistent with a 2025 Lancet Respiratory Medicine meta-analysis of CPAP therapy and all-cause mortality. According to cpap.com’s 2025 statistics compilation, OSA is associated with a 48% increased risk of coronary heart disease, with over 50% of people with heart failure having some form of sleep-disordered breathing, and up to 74% of atrial fibrillation patients potentially having OSA.

The mechanisms are multiple and interacting. Each apnea event produces hypoxia (low oxygen), sympathetic nervous system activation, surges in blood pressure, and oxidative stress — all of which promote endothelial inflammation, arterial stiffness, and atherosclerosis over time. The intermittent hypoxia of OSA is particularly damaging to cardiac tissue: the heart works harder to maintain perfusion during apnea events, and the repeated oxygen drops and restorations create ischaemia-reperfusion injury at the cellular level. Treating OSA with CPAP therapy has been shown to reduce blood pressure, improve cardiac function, and reduce cardiovascular event risk in multiple randomised controlled trials — confirming the causal relationship between sleep-disordered breathing and cardiovascular disease.

Sleep Apnea and Diabetes: A Bidirectional and Frequently Missed Link

The relationship between obstructive sleep apnea and type 2 diabetes is bidirectional and clinically significant. OSA promotes insulin resistance through multiple mechanisms: intermittent hypoxia triggers cortisol and catecholamine release that impairs insulin sensitivity; sleep fragmentation reduces slow-wave sleep, which is required for glucose metabolism regulation; and the resulting daytime fatigue increases cravings for high-glycaemic foods while reducing the physical activity that would otherwise buffer insulin resistance. According to cpap.com’s 2025 statistics, up to 67% of people with OSA may have prediabetes, and some researchers estimate that up to 83% of people with type 2 diabetes have OSA. Conversely, diabetes promotes OSA through diabetic neuropathy affecting the upper airway muscles, and through the obesity that frequently accompanies insulin resistance. The clinical implication is that any patient with type 2 diabetes or prediabetes should be screened for OSA, and any patient with high-risk OSA findings should have blood glucose evaluated.

Sleep Apnea and Blood Pressure: One of the Most Common Secondary Causes of Hypertension

Sleep apnea is one of the most common — and most frequently overlooked — secondary causes of hypertension. According to cpap.com’s comprehensive statistics, up to 50% of OSA cases have co-existing high blood pressure, with people with even mild OSA being more than twice as likely to have hypertension compared to those with no apnea events. People with moderate or more severe OSA could be 180% more likely to be diagnosed with hypertension, and researchers estimate that 89% of young adults with unexplained high blood pressure may have undiagnosed OSA. This association has a mechanistic basis: each apnea event triggers a sympathetic surge that spikes blood pressure — and with dozens to hundreds of such events per night, the sympathetic nervous system becomes chronically overactivated, resetting the basal blood pressure upward. OSA-associated hypertension is distinctive in that it tends to be non-dipping — blood pressure does not fall during sleep as it normally should — a pattern that significantly amplifies cardiovascular risk. Treating OSA, in patients with treatment-resistant hypertension, often produces meaningful blood pressure reduction independently of antihypertensive medication.

Sleep Apnea in Women: Why It Gets Missed and How It Presents Differently

Sleep apnea in women is significantly underdiagnosed compared to men — historically diagnosed at a 2-3:1 male-to-female ratio, despite the true prevalence gap being narrower. The ResMed 2025 Lancet Respiratory Medicine study projected a 65% relative increase in OSA prevalence among women by 2050, reaching 30.4 million cases, attributed to factors including an aging female population and significant underdiagnosis of existing cases. Women with OSA present differently than men in several important ways: they are more likely to report insomnia, fatigue, depression, and headaches rather than the classic loud snoring and observed apneas; they are more likely to have predominantly hypopneas (partial airway restriction) rather than complete apneas, which may be classified as mild on AHI criteria despite causing significant oxygen desaturation; and OSA in women frequently goes unrecognised because partners are less likely to report symptoms (women are less likely to sleep with a snoring partner or to have their snoring commented on). Hormonal factors also play a role: progesterone and estrogen protect against upper airway collapse, meaning OSA risk increases substantially at menopause — yet menopausal women presenting with fatigue and sleep problems are far less likely to be referred for sleep studies than men with similar symptoms.

Obstructive vs Central Sleep Apnea: Understanding the Difference

Sleep apnea encompasses two distinct conditions with different causes and treatments. Obstructive sleep apnea (OSA) — by far the most common form, accounting for approximately 84% of cases — is caused by physical collapse of the upper airway during sleep. The airway becomes narrowed or completely blocked by the relaxation of throat muscles, excess tissue around the throat (particularly in overweight individuals), or anatomical factors such as a large tongue, enlarged tonsils, or a recessed jaw. The brain’s respiratory drive continues during OSA events — there is a sustained effort to breathe, but airflow is mechanically obstructed. Central sleep apnea (CSA) is less common and involves a failure of the brain’s respiratory control centre to send appropriate signals to the breathing muscles — meaning breathing simply stops without any obstruction or effort. CSA is associated with heart failure, stroke, opioid use, and high altitude, and requires different treatment from OSA (CPAP may worsen some CSA patterns). Complex or mixed sleep apnea involves both components. This check screens primarily for OSA, the most prevalent form.

How Is Sleep Apnea Diagnosed? Polysomnography vs Home Sleep Tests

Sleep apnea diagnosis requires objective measurement of breathing events during sleep — it cannot be confirmed by symptoms, questionnaires, or clinical examination alone, though these tools identify who needs testing. The gold standard diagnostic tool is overnight polysomnography (PSG) — a laboratory-based sleep study that monitors airflow, blood oxygen saturation, respiratory effort, EEG brain activity, ECG, and body position simultaneously over a full night. PSG provides the most comprehensive data and is particularly important when central sleep apnea, parasomnias, or complex sleep disorders are suspected alongside OSA. Home sleep testing (HST) — which measures airflow, respiratory effort, blood oxygen saturation, and heart rate via a portable device worn overnight — is now the standard first-line diagnostic approach for patients with a high pre-test probability of uncomplicated OSA, based on clinical guidelines from the American Academy of Sleep Medicine (AASM). HST costs significantly less than laboratory PSG and is widely available through telehealth platforms and home testing services. The primary measure used for OSA diagnosis and severity classification is the Apnea-Hypopnea Index (AHI): AHI 5–14 = mild OSA; AHI 15–29 = moderate OSA; AHI 30+ = severe OSA.

Sleep Apnea Treatment Options: CPAP, Oral Appliances, Surgery, and Lifestyle

Treatment for obstructive sleep apnea has a strong evidence base and produces significant improvements in sleep quality, daytime function, blood pressure, cardiovascular risk, and quality of life. Continuous positive airway pressure (CPAP) therapy — delivering pressurised air through a nasal or full-face mask to keep the airway open during sleep — remains the gold standard first-line treatment for moderate and severe OSA, and many cases of mild OSA with significant symptoms. Modern CPAP devices, including the ResMed AirSense 11, use auto-titrating algorithms that adjust pressure breath-by-breath and connect to companion apps (myAir) for remote monitoring and compliance tracking. Adherence is the primary challenge — approximately 30–50% of patients discontinue CPAP within 12 months — making alternative options clinically important. Mandibular advancement devices (MADs) — oral appliances made by sleep dentists that advance the lower jaw to prevent airway collapse — are the most evidence-supported CPAP alternative for mild to moderate OSA, with meta-analyses showing comparable efficacy to CPAP in AHI reduction and patient preference. Surgical options including uvulopalatopharyngoplasty (UPPP) and the newer hypoglossal nerve stimulation (Inspire therapy) are appropriate for specific anatomical patterns or CPAP non-responders. Weight loss of 10–15% of body weight has been shown to produce clinically meaningful AHI reduction in overweight individuals, and is the most impactful single non-device intervention. Avoiding alcohol within 3–4 hours of sleep, positional therapy for position-dependent OSA, and nasal decongestion address contributing factors. The FDA approved tirzepatide (Zepbound) specifically for moderate-to-severe OSA in adults with obesity in 2024 — the first drug approved for OSA — with clinical trials showing AHI reduction of approximately 30 events per hour.

Untreated Sleep Apnea Risks: What Happens If You Do Not Address It

The consequences of untreated obstructive sleep apnea accumulate gradually and affect multiple organ systems simultaneously. Cardiovascular consequences — documented above — include hypertension, coronary artery disease, heart failure, atrial fibrillation, and stroke, with untreated severe OSA increasing mortality risk by 71% according to the 2026 Imperial College research. Metabolic consequences include progression of insulin resistance to type 2 diabetes, weight gain (sleep fragmentation increases ghrelin and reduces leptin, driving increased appetite), and non-alcoholic fatty liver disease. Neurological consequences include cognitive impairment — OSA accelerates hippocampal volume loss and has been linked to increased Alzheimer’s disease risk in multiple longitudinal studies — as well as depression, anxiety, and reduced quality of life. Occupational and safety consequences are significant: people with untreated OSA are 2–7 times more likely to be involved in traffic accidents, and OSA-related drowsy driving is estimated to cause thousands of deaths annually in the US. Researchers have estimated that treating all affected drivers could save 980 lives per year. For anyone with a high-risk STOP-Bang profile, the question is not whether to investigate — it is how urgently.